We found that treatment with AREG antibody reduced the overall tumor burden (based on blood Gluc levels, p = 0.012) (Fig. 6a, b); however, there was no significant reduction in the cell pellet volume of malignant ascites (Fig. 6c), suggesting that AREG antibody did not reduce the growth of CL31 tumor cells in the ascites. The gene discussed is AREG; the disease is neoplasm.